The Bull Case for PCSK9 (AMGN, SNY, REGN, PFE): Why Estimates Are Too Low
Background – PCSK9 Inhibitors and New Cholesterol Treatment Guidelines Amgen and Sanofi / Regeneron presented phase III LDL-C (‘bad cholesterol’) lowering data for their respective PCSK9 inhibitors (evolocumab and alirocumab,…